A Universal Platform for Identification of Novel Lung Cancer Biomarkers Based on Exosomes
Technical Report,01 Jul 2016,30 Jun 2017
Leland Stanford Junior University Palo Alto United States
Pagination or Media Count:
Circulating tumor-derived extracellular vesicles EVs have emerged as a promising source for identifying cancer biomarkers for early cancer detection. However, the clinical utility of EVs has thus far been limited by the fact that most EV isolation methods are tedious, nonstandardized, and require bulky instrumentation such as ultracentrifugation UC. Here, we report a size-based EV isolation tool called ExoTIC exosome total isolation chip, which is simple, easy-to-use, modular, and facilitates high-yield and high-purity EV isolation from biofluids. ExoTIC achieves an EV yield 41000-fold higher than that with UC, and EV-derived protein and microRNA levels are well-correlated between the two methods. Moreover, we demonstrate that ExoTIC is a modular platform that can sort a heterogeneous population of cancer cell line EVs based on size. Further, we utilize ExoTIC to isolate EVs from cancer patient clinical samples, including plasma, urine, and lavage, demonstrating the devices broad applicability to cancers and other diseases. Finally, the ability of ExoTIC to efficiently isolate EVs from small sample volumes opens up avenues for preclinical studies in small animal tumor models and for point-of-care EV-based clinical testing from fingerprick quantities 10-100 muL of blood.
- Medicine and Medical Research
- Genetic Engineering and Molecular Biology